Phreesia, Inc. (NYSE: PHR) (“Phreesia”) announced financial results today for the fiscal first quarter ended April 30, 2021.
"We carried the momentum of the strong finish to our fiscal year 2021 into the first quarter of fiscal 2022. As we look ahead, we’re excited to continue providing health systems, hospitals and ambulatory providers with tools that will help them optimize their performance and improve the patient experience,” said Phreesia CEO Chaim Indig.
Fiscal First Quarter 2022 Highlights
- Revenue was $48.3 million in the quarter as compared to $33.4 million in the same period in the prior year, an increase of 45%.
- Average number of provider clients was 1,902 in the quarter as compared to 1,632 in the same period in the prior year, an increase of 17%.
- Average revenue per provider client was $20,222 in the quarter compared to $16,735 in the same period in the prior year, an increase of 21%.
- Adjusted EBITDA was positive $0.1 million in the quarter compared to positive $1.5 million in the same period in the prior year.
- Cash and cash equivalents as of April 30, 2021 was $450.7 million, an increase of $231.9 million compared to January 31, 2021, driven primarily by our follow-on offering of common stock, which generated net proceeds of $245.8 million.
Outlook for Fiscal 2022
We are increasing our revenue outlook for fiscal 2022 to a range of $191 million to $194 million from the previous range of $178 million to $186 million. We continue to expect our overall cash outflow to increase in fiscal 2022 compared to fiscal 2021 as we continue to ramp up hiring and infrastructure across the organization to support our anticipated growth.
Conference Call Information
The Company will hold a conference call on Friday, June 4, 2021, at 8:30 a.m. Eastern Time to review the Company’s first fiscal quarter financial results. To participate in the Company’s live conference call and webcast, please dial (866) 211-4557 (or (647) 689-6750 for international participants) using conference code number 3966898 or visit the “Events & Presentations” section of ir.phreesia.com. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for approximately 90 days.
Recent Events
COVID-19
The impact of the COVID-19 (a novel strain of coronavirus) pandemic has been widespread and rapidly evolving. Over the last six months, several vaccines for COVID-19 received FDA approval and are currently being administered across the country. To date, more than a third of Americans are fully vaccinated against the virus. Despite the promising vaccination rates and many states' reopening plans, we believe COVID-19 may continue to impact the normal operations of our clients, which are primarily healthcare providers. As more individuals are vaccinated, we expect these impacts to be diminished.
Phreesia, Inc.
|
|||||||
|
April 30, 2021 |
|
January 31, 2021 |
||||
|
(unaudited) |
|
|
||||
Assets |
|
|
|
||||
Current: |
|
|
|
||||
Cash and cash equivalents |
$ |
450,680 |
|
|
$ |
218,781 |
|
Settlement assets |
16,788 |
|
|
15,488 |
|
||
Accounts receivable, net of allowance for doubtful accounts of $666 and $699 as of April 30, 2021 and January 31, 2021, respectively |
29,964 |
|
|
29,052 |
|
||
Deferred contract acquisition costs |
1,895 |
|
|
1,693 |
|
||
Prepaid expenses and other current assets |
7,906 |
|
|
7,254 |
|
||
Total current assets |
507,233 |
|
|
272,268 |
|
||
Property and equipment, net of accumulated depreciation and amortization of $43,442 and $40,148 as of April 30, 2021 and January 31, 2021, respectively |
25,068 |
|
|
26,660 |
|
||
Capitalized internal-use software, net of accumulated amortization of $26,998 and $25,476 as of April 30, 2021 and January 31, 2021, respectively |
11,225 |
|
|
10,476 |
|
||
Operating lease right-of-use assets |
2,497 |
|
|
2,654 |
|
||
Deferred contract acquisition costs |
2,438 |
|
|
1,248 |
|
||
Intangible assets, net of accumulated amortization of $653 and $525 as of April 30, 2021 and January 31, 2021, respectively |
2,597 |
|
|
2,725 |
|
||
Deferred tax asset |
533 |
|
|
658 |
|
||
Goodwill |
8,211 |
|
|
8,307 |
|
||
Other assets |
1,401 |
|
|
1,670 |
|
||
Total assets |
$ |
561,203 |
|
|
$ |
326,666 |
|
Liabilities and Stockholders’ Equity |
|
|
|
||||
Current: |
|
|
|
||||
Settlement obligations |
$ |
16,788 |
|
|
$ |
15,488 |
|
Current portion of debt and finance lease liabilities |
4,103 |
|
|
4,864 |
|
||
Current portion of operating lease liabilities |
1,153 |
|
|
1,087 |
|
||
Accounts payable |
313 |
|
|
4,389 |
|
||
Accrued expenses |
15,116 |
|
|
18,324 |
|
||
Deferred revenue |
13,223 |
|
|
10,838 |
|
||
Total current liabilities |
50,696 |
|
|
54,990 |
|
||
Long-term debt and finance lease liabilities |
5,532 |
|
|
6,471 |
|
||
Operating lease liabilities, non-current |
1,701 |
|
|
1,899 |
|
||
Total liabilities |
57,929 |
|
|
63,360 |
|
||
Commitments and contingencies |
|
|
|
||||
Stockholders’ Equity: |
|
|
|
||||
Common stock, $0.01 par value - 500,000,000 shares authorized as of April 30, 2021 and January 31, 2021, respectively; 50,270,229 and 44,880,883 shares issued as of April 30, 2021 and January 31, 2021, respectively |
503 |
|
|
449 |
|
||
Additional paid-in capital |
831,632 |
|
|
579,599 |
|
||
Accumulated deficit |
(322,751 |
) |
|
(311,777 |
) |
||
Treasury stock, at cost, 119,138 and 99,520 shares at April 30, 2021 and January 31, 2021, respectively |
(6,110 |
) |
|
(4,965 |
) |
||
Total Stockholders’ Equity |
503,274 |
|
|
263,306 |
|
||
Total Liabilities and Stockholders’ Equity |
$ |
561,203 |
|
|
$ |
326,666 |
|
Phreesia, Inc.
|
|||||||
|
Three months ended April 30, |
||||||
|
2021 |
|
2020 |
||||
Revenue: |
|
|
|
||||
Subscription and related services |
$ |
21,819 |
|
|
$ |
15,599 |
|
Payment processing fees |
16,644 |
|
|
11,707 |
|
||
Life sciences |
9,828 |
|
|
6,090 |
|
||
Total revenues |
48,291 |
|
|
33,396 |
|
||
Expenses: |
|
|
|
||||
Cost of revenue (excluding depreciation and amortization) |
8,534 |
|
|
4,734 |
|
||
Payment processing expense |
9,725 |
|
|
6,848 |
|
||
Sales and marketing |
15,012 |
|
|
9,434 |
|
||
Research and development |
8,054 |
|
|
5,005 |
|
||
General and administrative |
12,671 |
|
|
8,720 |
|
||
Depreciation |
3,297 |
|
|
2,268 |
|
||
Amortization |
1,651 |
|
|
1,353 |
|
||
Total expenses |
58,944 |
|
|
38,362 |
|
||
Operating loss |
(10,653 |
) |
|
(4,966 |
) |
||
Other income (expense), net |
66 |
|
|
(715 |
) |
||
Interest (expense) income, net |
(238 |
) |
|
(320 |
) |
||
Total other expense, net |
(172 |
) |
|
(1,035 |
) |
||
Loss before provision for income taxes |
(10,825 |
) |
|
(6,001 |
) |
||
Provision for income taxes |
(149 |
) |
|
(111 |
) |
||
Net loss |
$ |
(10,974 |
) |
|
$ |
(6,112 |
) |
Net loss per share attributable to common stockholders, basic and diluted |
$ |
(0.24 |
) |
|
$ |
(0.16 |
) |
Weighted-average common shares outstanding, basic and diluted |
45,416,431 |
|
|
37,308,084 |
|
||
|
|
|
|
||||
Phreesia, Inc.
|
||||||||
|
|
Three Months Ended April 30, |
||||||
|
2021 |
|
2020 |
|||||
Operating activities: |
|
|
|
|
||||
Net loss |
|
$ |
(10,974 |
) |
|
$ |
(6,112 |
) |
Adjustments to reconcile net loss to net cash (used in) provided by operating activities: |
|
|
|
|
||||
Depreciation and amortization |
|
4,948 |
|
|
3,621 |
|
||
Stock-based compensation expense |
|
5,774 |
|
|
2,872 |
|
||
Amortization of debt discount |
|
72 |
|
|
126 |
|
||
Cost of Phreesia hardware purchased by customers |
|
135 |
|
|
172 |
|
||
Deferred contract acquisition cost amortization |
|
575 |
|
|
525 |
|
||
Non-cash operating lease expense |
|
256 |
|
|
389 |
|
||
Deferred tax asset |
|
125 |
|
|
56 |
|
||
Changes in operating assets and liabilities: |
|
|
|
|
||||
Accounts receivable |
|
(912 |
) |
|
(2,245 |
) |
||
Prepaid expenses and other assets |
|
(809 |
) |
|
1,614 |
|
||
Deferred contract acquisition costs |
|
(1,967 |
) |
|
(714 |
) |
||
Accounts payable |
|
(1,068 |
) |
|
(998 |
) |
||
Accrued expenses and other liabilities |
|
(3,678 |
) |
|
1,871 |
|
||
Lease liability |
|
(335 |
) |
|
(502 |
) |
||
Deferred revenue |
|
2,385 |
|
|
1,228 |
|
||
Net cash (used in) provided by operating activities |
|
(5,473 |
) |
|
1,903 |
|
||
Investing activities: |
|
|
|
|
||||
Capitalized internal-use software |
|
(2,916 |
) |
|
(1,160 |
) |
||
Purchase of property and equipment |
|
(3,983 |
) |
|
(1,917 |
) |
||
Net cash used in investing activities |
|
(6,899 |
) |
|
(3,077 |
) |
||
Financing activities: |
|
|
|
|
||||
Proceeds from issuance of common stock in equity offerings, net of underwriters' discounts and commissions |
|
245,813 |
|
|
— |
|
||
Proceeds from issuance of common stock upon exercise of stock options |
|
1,356 |
|
|
1,736 |
|
||
Treasury stock to satisfy tax withholdings on stock compensation awards |
|
(1,145 |
) |
|
— |
|
||
Payments of offering costs |
|
(30 |
) |
|
— |
|
||
Finance lease payments |
|
(1,050 |
) |
|
(525 |
) |
||
Principal payments on financing arrangements |
|
(673 |
) |
|
— |
|
||
Loan facility fee payment |
|
— |
|
|
(100 |
) |
||
Net cash provided by financing activities |
|
$ |
244,271 |
|
|
$ |
1,111 |
|
Net increase (decrease) in cash and cash equivalents |
|
231,899 |
|
|
(63 |
) |
||
Cash and cash equivalents – beginning of period |
|
218,781 |
|
|
90,315 |
|
||
Cash and cash equivalents – end of period |
|
$ |
450,680 |
|
|
$ |
90,252 |
|
|
|
|
|
|
||||
Supplemental information of non-cash investing and financing information: |
|
|
|
|
||||
Right-of-use assets obtained in exchange for operating lease liabilities |
|
$ |
81 |
|
|
$ |
3,185 |
|
Property and equipment acquisitions through finance leases |
|
$ |
203 |
|
|
$ |
827 |
|
Deferred offering costs included in accounts payable and accrued expenses |
|
$ |
362 |
|
|
$ |
— |
|
Purchase of property and equipment and capitalized software included in accounts payable |
|
$ |
351 |
|
|
$ |
791 |
|
Cash payments for: |
|
|
|
|
||||
Interest |
|
$ |
156 |
|
|
$ |
306 |
|
Non-GAAP financial measures
Adjusted EBITDA is a supplemental measure of our performance that is not required by, or presented in accordance with, GAAP. Adjusted EBITDA is not a measurement of our financial performance under GAAP and should not be considered as an alternative to net income or loss or any other performance measure derived in accordance with GAAP, or as an alternative to cash flows from operating activities as a measure of our liquidity. We define Adjusted EBITDA as net income or loss before interest expense (income), net, provision for (benefit from) income taxes, depreciation and amortization, and before stock-based compensation expense, change in fair value of contingent consideration liabilities and other (income) expense, net.
We have provided below a reconciliation of Adjusted EBITDA to net loss, the most directly comparable GAAP financial measure. We have presented Adjusted EBITDA in this press release and our Annual Report on Form 10-K because it is a key measure used by our management and board of directors to understand and evaluate our core operating performance and trends, to prepare and approve our annual budget, and to develop short and long-term operational plans. In particular, we believe that the exclusion of the amounts eliminated in calculating Adjusted EBITDA can provide a useful measure for period-to-period comparisons of our core business. Accordingly, we believe that Adjusted EBITDA provides useful information to investors and others in understanding and evaluating our operating results in the same manner as our management and board of directors.
Our use of Adjusted EBITDA has limitations as an analytical tool, and you should not consider it in isolation or as a substitute for analysis of our financial results as reported under GAAP. Some of these limitations are as follows:
- Although depreciation and amortization expense are non-cash charges, the assets being depreciated and amortized may have to be replaced in the future, and Adjusted EBITDA does not reflect cash capital expenditure requirements for such replacements or for new capital expenditure requirements;
- Adjusted EBITDA does not reflect: (1) changes in, or cash requirements for, our working capital needs; (2) the potentially dilutive impact of non-cash stock-based compensation; (3) tax payments that may represent a reduction in cash available to us; or (4) Interest expense (income), net; and
- Other companies, including companies in our industry, may calculate Adjusted EBITDA or similarly titled measures differently, which reduces its usefulness as a comparative measure.
Because of these and other limitations, you should consider Adjusted EBITDA along with other GAAP-based financial performance measures, including various cash flow metrics, net loss, and our GAAP financial results. The following table presents a reconciliation of Adjusted EBITDA to net loss for each of the periods indicated:
Phreesia, Inc.
|
||||||||
|
|
Three Months ended April 30, |
||||||
(in thousands) |
2021 |
|
2020 |
|||||
Net loss |
|
$ |
(10,974 |
) |
|
$ |
(6,112 |
) |
Interest expense (income), net |
|
238 |
|
|
320 |
|
||
Provision for income taxes |
|
149 |
|
|
111 |
|
||
Depreciation and amortization |
|
4,948 |
|
|
3,621 |
|
||
Stock-based compensation expense |
|
5,774 |
|
|
2,872 |
|
||
Other (income) expense, net |
|
(66 |
) |
|
715 |
|
||
Adjusted EBITDA |
|
$ |
69 |
|
|
$ |
1,527 |
|
Phreesia, Inc.
|
||||||||
|
|
Three Months ended April 30, |
||||||
(in thousands) |
|
2021 |
|
2020 |
||||
GAAP operating expenses |
|
|
|
|
||||
General and administrative |
|
12,671 |
|
|
8,720 |
|
||
Sales and marketing |
|
15,012 |
|
|
9,434 |
|
||
Research and development |
|
8,054 |
|
|
5,005 |
|
||
Cost of revenue |
|
8,534 |
|
|
4,734 |
|
||
|
|
$ |
44,271 |
|
|
$ |
27,893 |
|
Stock compensation included in GAAP operating expenses |
|
|
|
|
||||
General and administrative |
|
$ |
2,918 |
|
|
$ |
1,606 |
|
Sales and marketing |
|
1,646 |
|
|
728 |
|
||
Research and development |
|
844 |
|
|
452 |
|
||
Cost of revenue |
|
366 |
|
|
86 |
|
||
|
|
$ |
5,774 |
|
|
$ |
2,872 |
|
Adjusted operating expenses |
|
|
|
|
||||
General and administrative |
|
$ |
9,753 |
|
|
$ |
7,114 |
|
Sales and marketing |
|
13,366 |
|
|
8,706 |
|
||
Research and development |
|
7,210 |
|
|
4,553 |
|
||
Cost of revenue |
|
8,168 |
|
|
4,648 |
|
||
|
|
$ |
38,497 |
|
|
$ |
25,021 |
|
Phreesia, Inc.
|
||||||||
|
|
Three months ended April 30, |
||||||
|
|
2021 |
|
2020 |
||||
Key Metrics: |
|
|
|
|
||||
Provider clients (average over period) |
|
1,902 |
|
|
1,632 |
|
||
Average revenue per provider client |
|
$ |
20,222 |
|
|
$ |
16,735 |
|
- Provider clients. We define provider clients as the average number of healthcare provider organizations that generate revenue each month during the applicable period. In cases where we act as a subcontractor providing white-label services to our partner's clients, we treat the contractual relationship as a single provider client. We believe growth in the number of provider clients is a key indicator of the performance of our business and depends, in part, on our ability to successfully develop and market our Platform to healthcare provider organizations that are not yet clients. While growth in the number of provider clients is an important indicator of expected revenue growth, it also informs our management of the areas of our business that will require further investment to support expected future provider client growth. For example, as the number of provider clients increases, we may need to add to our customer support team and invest to maintain effectiveness and performance of our Platform and software for our provider clients and their patients.
- Average revenue per provider client. We define average revenue per provider client as the total subscription and related services and payment processing revenue generated from provider clients in a given period divided by the average number of provider clients that generate revenue each month during that same period. We are focused on continually delivering value to our provider clients and believe that our ability to increase average revenue per provider client is an indicator of the long-term value of the Phreesia platform.
Additional Information
|
||||||||
|
|
Three months ended April 30, |
||||||
|
|
2021 |
|
2020 |
||||
Patient payment volume (in millions) |
|
$ |
701 |
|
|
$ |
454 |
|
Payment facilitator volume percentage |
78 |
% |
84 |
% |
||||
- Patient payment volume. We believe that patient payment volume is an indicator of both the underlying health of our provider clients’ businesses and the continuing shift of healthcare costs to patients. We measure patient payment volume as the total dollar volume of transactions between our provider clients and their patients utilizing our payment platform, including via credit and debit cards that we process as a payment facilitator as well as cash and check payments and credit and debit transactions for which Phreesia acts as a gateway to other payment processors.
- Payment facilitator volume percentage. We define payment facilitator volume percentage as the volume of credit and debit card patient payment volume that we process as a payment facilitator as a percentage of total patient payment volume. Payment facilitator volume is a major driver of our payment processing revenue.
Available Information
Phreesia intends to use its Company website (including its Investor Relations website) as well as its Facebook, Twitter and LinkedIn accounts as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.
Forward Looking Statements
This press release includes express or implied statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. Forward-looking statements involve substantial risks and uncertainties. Forward-looking statements generally relate to future events or our future financial or operating performance and may contain projections of our future results of operations or of our financial information or state other forward-looking information. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Although we believe that the expectations reflected in these forward-looking statements are reasonable, these statements relate to future events or our future operational or financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward looking statements. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control, including, without limitation, statements about our future financial performance, including our revenue, cash flows, costs of revenue and operating expenses; our anticipated growth; our predictions about our industry; the impact of the COVID-19 pandemic on our business and our ability to attract, retain and cross-sell to healthcare provider clients. The forward-looking statements contained in this release are also subject to other risks and uncertainties, including those more fully described in our filings with the Securities and Exchange Commission (“SEC”), including in our Quarterly Report on Form 10-Q for the fiscal year ended April 30, 2021 that will be filed with the SEC following this earnings release. The forward-looking statements in this press release speak only as of the date on which the statements are made. We undertake no obligation to update, and expressly disclaim the obligation to update, any forward-looking statements made in this press release to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.
This press release includes certain non-GAAP financial measures as defined by SEC rules. We have provided a reconciliation of those measures to the most directly comparable GAAP measures.
ABOUT PHREESIA
Phreesia gives healthcare organizations a suite of robust applications to manage the patient intake process. Our innovative SaaS platform engages patients in their care and provides a modern, consistent experience, while enabling healthcare organizations to optimize their staffing, boost profitability and enhance clinical care.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210603005887/en/
Contacts
Investors:
Balaji Gandhi
Phreesia, Inc.
investors@phreesia.com
(929) 506-4950
Media:
Annie Harris
Phreesia, Inc.
aharris@phreesia.com
(929) 526-2611
